Evaluating aminophylline's effects on lung function in obese patients during bariatric surgery
Impacts of Aminophylline on Perioperative Lung Mechanics in COPD Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery: A Prospective Randomized Double Blinded Trial
This study is testing if adding aminophylline to a common medication during weight loss surgery can help improve lung function and oxygen levels in obese patients with breathing problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 60 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta, El-Gharbia) |
| Trial ID | NCT06125665 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the impact of adding aminophylline to dexmedetomidine intravenous infusion during laparoscopic bariatric surgery on the oxygenation and lung mechanics of morbidly obese patients with chronic obstructive pulmonary disease (COPD). The research focuses on patients aged 20 to 60 who are scheduled for surgery and have a BMI greater than 40 kg/m2. By examining the combined effects of these medications, the study seeks to improve recovery outcomes for patients with respiratory complications related to obesity. The methodology includes monitoring lung function and oxygenation levels during and after the surgical procedure.
Who should consider this trial
Good fit: Ideal candidates are morbidly obese patients aged 20 to 60 with a BMI over 40 kg/m2 and diagnosed obstructive lung disease.
Not a fit: Patients with significant coexisting diseases, arrhythmias, or those allergic to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance postoperative recovery and lung function in morbidly obese patients with COPD undergoing bariatric surgery.
How similar studies have performed: Previous studies have shown positive outcomes with dexmedetomidine in similar patient populations, but the combination with aminophylline is less commonly tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 20 to 60 years. * Patients scheduled for laparoscopic bariatric surgery not exceeding three hours under general anesthesia. * American Society of Anesthesiologists (ASA) class II to III. * Patients who had no previous abdominal surgery. * Patients with a body mass index (BMI) greater than 40 kg/m2and suffered obstructive lung disease diagnosed by pulmonary function tests (; forced vital capacity (FEV1\\FVC) \< 70%). * Patients who are psychologically normal. Exclusion Criteria: * Patients who refuse to participate. * Those with arrhythmia or receiving anti-arrhythmic medications. * Those with significant coexisting diseases (e.g. kidney, heart, liver). * Those with known allergy to any of allocated drugs. * Those with excessive intraoperative blood loss more than allowable amount to every patient.
Where this trial is running
Tanta, El-Gharbia
- Tanta University — Tanta, El-Gharbia, Egypt (Recruiting)
Study contacts
- Study coordinator: Soliman R Naser, MD
- Email: Soliman.naser@med.tanta.edu.eg
- Phone: 00201097929609
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.